Studying tumor cells in blood disorders with inflammation
Looks at tumor cells in people with monoclonal gammopathies and inflammatory symptoms.
Plain-language title generated from the registry record
Registry title: Establishment of Genomic, Transcriptomic and Functional Characteristics of Tumor Cells in Hyperinflammatory Hemopathies
Key facts
- Where
- Paris, FranceSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a monoclonal gammopathy or a related blood condition who also have a fever of unknown cause with certain symptoms.
- Age
- Over 18 years
- Sex
- All sexes can join.
- Disease stage
- Myelodysplastic syndrome, multiple myeloma, monoclonal gammopathy of undetermined significance, or Schnitzler's syndrome, together with a fever of undetermined cause and at least one of: rash, joint pain or arthritis, inflammation of the lining of organs (serositis), abdominal pain.
Main reasons for not taking part
- Cannot give free and informed consent
- Under guardianship, curatorship or safeguarding of justice
- Does not speak French
- Cannot answer questions or express themselves
- Another diagnosis that may explain the symptoms
Read by machine on 12 November 2026.
Where in France
- Service de Médecine InterneParis, FranceContact: Sophie GEORGIN-LAVIALLE, MD PhDNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Trial code
- NCT04702932
- Record updated
- 11 January 2021
- Original description
Patients with monoclonal gammopathies either benign or malignant may develop inflammatory symptoms such as Schnitzler syndrome. We proposed to name those cases as monoclonal gammopathy of inflammatory significance, or MGIS.Read full original descriptionShow less
Establishment of Genomic, Transcriptomic and Functional Characteristics of Tumor Cells in Hyperinflammatory Hemopathies
Patients with monoclonal gammopathies either benign or malignant may develop inflammatory symptoms such as Schnitzler syndrome. We proposed to name those cases as monoclonal gammopathy of inflammatory significance, or MGIS.
The aim of the study is to search for inflammatory pathway that may be activated in case MGIS and to search if the genetic of tumoral cell could explain those activations.
Inclusion: Patient over 18 years of age with the capacity to give express free and informed consent; Patient followed in one of the services participating in the study and meeting the 2 following conditions; have myelodysplastic syndrome, or multiple myeloma, or monoclonal gammopathy of undetermined significance, or Schnitzler's syndrome; have a fever of undetermined etiology associated with one of the following symptoms: rash, arthralgia or arthritis, serositis, abdominal pain.
Exclusion: Patient incapable of giving express free and informed consent; Subject under guardianship, curatorship or safeguarding of justice; Subject does not speak French; Subject incapable of answering questions or expressing himself/herself; Presence of a differential diagnosis that may explain the patient's symptoms.